Jump to content

LY-344545: Difference between revisions

Browse history interactively
Page 1
Page 2
← Previous edit
Content deleted Content added
VisualWikitext
CheMoBot (talk | contribs)
Bots
141,565 edits
Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (
 
(26 intermediate revisions by 23 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{drugbox
{{Drugbox
⚫
| verifiedrevid = 280823046
| Watchedfields = changed
| IUPAC_name =
⚫
| verifiedrevid = 424883636
| image = LY-344,545_structure.png
| IUPAC_name = (αS)-α-Amino-α-[(1R,2R)-2-carboxycyclopropyl]-9H-xanthene-9-propanoic acid
⚫
| width = 160
| image = LY-344545 Structure.svg
⚫
| CAS_number =
⚫
| width = 160
⚫
| ATC_prefix =
⚫
| ATC_suffix =
| PubChem =
⚫
| DrugBank =
⚫
| C=20|H=19|N=1|O=5
| molecular_weight = 353.37 g/mol
⚫
| bioavailability =
⚫
| protein_bound =
⚫
| metabolism =
⚫
| elimination_half-life =
⚫
| excretion =
⚫
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
⚫
| pregnancy_US = <!-- A / B / C / D / X -->
⚫
| pregnancy_category=
⚫
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
⚫
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
⚫
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
⚫
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
⚫
| legal_status =
⚫
| routes_of_administration =
⚫
}}


<!--Clinical data-->
⚫
'''LY-344,545''' is a research drug developed by the pharmaceutical company [[Eli Lilly and Company|Eli Lilly]], which acts as an [[Receptor antagonist|antagonist]] for the [[metabotropic glutamate receptor]] subtype [[Metabotropic glutamate receptor 5|mGluR<sub>5</sub>]]. It is an [[epimer]] of another metabotropic glutamate receptor antagonist, the [[Metabotropic glutamate receptor|mGluR<sub>2/3</sub>]]-selective [[LY-341,495]].<ref>Ornstein PL, Bleisch TJ, Arnold MB, Kennedy JH, Wright RA, Johnson BG, Tizzano JP, Helton DR, Kallman MJ, Schoepp DD, Hérin M. 2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability. ''Journal of Medicinal Chemistry''. 1998 Jan 29;41(3):358-78. PMID 9464367</ref><ref>Doherty AJ, Palmer MJ, Bortolotto ZA, Hargreaves A, Kingston AE, Ornstein PL, Schoepp DD, Lodge D, Collingridge GL. A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices. ''British Journal of Pharmacology''. 2000 Sep;131(2):239-44. PMID 10991916</ref>
| tradename =
⚫
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
⚫
| pregnancy_US = <!-- A / B / C / D / X -->
⚫
| pregnancy_category =
⚫
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
⚫
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
⚫
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
⚫
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
⚫
| legal_status =
⚫
| routes_of_administration =


<!--Pharmacokinetic data-->
⚫
| bioavailability =
⚫
| protein_bound =
⚫
| metabolism =
⚫
| elimination_half-life =
⚫
| excretion =


<!--Identifiers-->
⚫
| CAS_number = 201851-20-9
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 9ZSQ1C4209
⚫
| ATC_prefix =
⚫
| ATC_suffix =
| PubChem = 10618042
| ChemSpiderID = 8793407
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
⚫
| DrugBank =


<!--Chemical data-->
{{pharmacology-stub}}
⚫
| C=20 | H=19 | N=1 | O=5
| smiles = c1ccc2c(c1)C(c3ccccc3O2)C[C@]([C@@H]4C[C@H]4C(=O)O)(C(=O)O)N
| StdInChI = 1S/C20H19NO5/c21-20(19(24)25,15-9-13(15)18(22)23)10-14-11-5-1-3-7-16(11)26-17-8-4-2-6-12(14)17/h1-8,13-15H,9-10,21H2,(H,22,23)(H,24,25)/t13-,15-,20+/m1/s1
| StdInChIKey = VLZBRVJVCCNPRJ-RCDCFZSISA-N

⚫
}}


⚫
'''LY-344,545''' is a research drug developed by the pharmaceutical company [[Eli Lilly and Company|Eli Lilly]], which acts as an [[Receptor antagonist|antagonist]] for the [[metabotropic glutamate receptor]] subtype [[Metabotropic glutamate receptor 5|mGluR<sub>5</sub>]]. It is an [[epimer]] of another metabotropic glutamate receptor antagonist, the [[Metabotropic glutamate receptor|mGluR<sub>2/3</sub>]]-selective [[LY-341,495]].<ref>{{cite journal | vauthors = Ornstein PL, Bleisch TJ, Arnold MB, Kennedy JH, Wright RA, Johnson BG, Tizzano JP, Helton DR, Kallman MJ, Schoepp DD, Hérin M | display-authors = 6 | title = 2-substituted (2''SR'')-2-amino-2-((1''SR'',2''SR'')-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability | journal = Journal of Medicinal Chemistry | volume = 41 | issue = 3 | pages = 358–78 | date = January 1998 | pmid = 9464367 | doi = 10.1021/jm970498o }}</ref><ref>{{cite journal | vauthors = Doherty AJ, Palmer MJ, Bortolotto ZA, Hargreaves A, Kingston AE, Ornstein PL, Schoepp DD, Lodge D, Collingridge GL | display-authors = 6 | title = A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices | journal = British Journal of Pharmacology | volume = 131 | issue = 2 | pages = 239–44 | date = September 2000 | pmid = 10991916 | pmc = 1572327 | doi = 10.1038/sj.bjp.0703574 }}</ref>


== References ==
== References ==
{{Reflist|2}}
<references/>


{{Metabotropic glutamate receptor modulators}}


[[Category:Drugs developed by Eli Lilly and Company]]
{{Glutamate_receptor_ligands}}
[[Category:Eli Lilly and Company]]
[[Category:MGlu5 receptor antagonists]]
[[Category:Xanthenes]]
{{nervous-system-drug-stub}}
Retrieved from "https://en.wikipedia.org/wiki/Special:ComparePages"